Imperative Care Announces $100 Million Financing
Imperative Care announced $100 million in financing to support continued growth and innovation in thromboembolic disease care.
Pioneering Medical Innovations
Pioneering Medical Innovations
Imperative Care announced $100 million in financing to support continued growth and innovation in thromboembolic disease care.
SOL-1 met its superiority primary endpoint, the first successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment.
Ocular announced it would report topline SOL-1 Phase 3 data on February 17, 2026, with detailed data to follow at the 49th Macula Society Annual Meeting.
Dr. Ripal Gandhi completed the first commercial procedure with the Embrace Hydrogel Embolic System, marking the start of Instylla’s commercial launch following FDA approval.
Imperative Care launched the Zoom 4S Catheter, further expanding the Zoom Stroke System.
David W. Robinson, a commercial leader who helped architect the launch of EYLEA at Regeneron, was appointed Global Chief Commercial Officer.
The allay Hydrogel Cap received an Innovative Technology contract from Vizient, the nation’s largest provider-driven healthcare performance improvement company.
The first peer-reviewed clinical data on the allay Hydrogel Cap was published in Plastic and Reconstructive Surgery, Global Open, in a paper on early clinical experience treating and preventing symptomatic neuroma.
Late-breaking, real-world data from a multi-center review of stroke patients treated with the ADAPT 2.0 technique using the Zoom Stroke System were presented at the SVIN 2025 annual meeting.
Axtria launched its AI-Powered Launch Excellence for Emerging Pharma offering, integrating launch consulting, commercial operations, and a unified data foundation built on Axtria DataMAx.